IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, non-ferrous part and other features in order to deliver anesthesia and other IV fluids during various MRI procedures. MRI compatible IV infusion pump system includes the 3860+ MRI compatible IV infusion pump, single-use IV tubing sets, a non-magnetic pole and a lithium battery. In addition, it offers optional upgrade systems, including the 3865 Remote Display/Control, 3861 Side Car, Dose Error Reduction System (DERS) and SpO2 monitor.
Winter Springs, US
Size (employees)
68 (est)
IRadimed is headquartered in Winter Springs, US

IRadimed Office Locations

IRadimed has an office in Winter Springs
Winter Springs, US (HQ)
1025 Willa Springs Dr

IRadimed Data and Metrics

IRadimed Financial Metrics

IRadimed's revenue was reported to be $32.5 m in FY, 2016 which is a 3% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

32.5 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

26.3 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

7.2 m

EBIT (FY, 2016)

10.9 m

Market capitalization (21-Jun-2017)

97.8 m

Closing share price (21-Jun-2017)


Cash (31-Dec-2016)

17.7 m
IRadimed's current market capitalization is $97.8 m.
FY, 2014FY, 2015FY, 2016


15.7 m31.6 m32.5 m

Revenue growth, %


Cost of goods sold

3.4 m5.8 m6.2 m

Gross profit

12.2 m25.8 m26.3 m

Gross profit Margin, %


Sales and marketing expense

3.3 m4.7 m5.3 m

R&D expense

1.1 m1.8 m1.3 m

General and administrative expense

4.8 m7.8 m8.8 m

Operating expense total

9.2 m14.2 m15.4 m


3.1 m11.5 m10.9 m

EBIT margin, %


Pre tax profit

967 k11.6 m11 m

Income tax expense

967 k4.1 m3.7 m

Net Income

2.1 m7.5 m7.2 m
FY, 2014FY, 2015FY, 2016


9.5 m19.4 m17.7 m

Accounts Receivable

2 m3.9 m3.8 m


276.5 k318 k362.9 k

Current Assets

22.2 m34 m34.2 m


794.8 k905.6 k1.5 m

Total Assets

23.3 m35.2 m37.2 m

Accounts Payable

629.2 k1 m1.1 m

Current Liabilities

2.3 m2.9 m3.7 m

Additional Paid-in Capital

15.8 m19.3 m12.1 m

Retained Earnings

5.1 m12.7 m19.9 m

Total Equity

20.9 m31.9 m31.9 m

Financial Leverage

1.1 x1.1 x1.2 x
FY, 2014FY, 2015FY, 2016

Net Income

2.1 m7.5 m7.2 m

Depreciation and Amortization

149.1 k223.9 k248.3 k

Accounts Receivable

21.9 k(1.9 m)75.3 k


(154.9 k)(32 k)4.9 k

Accounts Payable

201.7 k376.3 k1.1 k

Cash From Operating Activities

2.6 m7.6 m9.4 m

Purchases of PP&E

(584 k)(298.7 k)(780.8 k)

Cash From Investing Activities

(8.3 m)(61.5 k)(1.9 m)

Cash From Financing Activities

12.7 m2.3 m(9.1 m)

Income Taxes Paid

1.2 m2.7 m3.4 m
Numbers are in $, USDY, 2016


477.9 k

Financial Leverage

1.2 x

IRadimed Operating Metrics

FY, 2016

Patents Issued


IRadimed Market Value History

IRadimed Revenue Breakdown

IRadimed Online and Social Media Presence

IRadimed Company Life and Culture

You may also be interested in